Bio News
U.S.-based Q BioPharma’s urticaria drug candidate CUE-221 met its primary endpoint in a phase 2 clinical trial.
At week 12, the CUE-221 treatment groups recorded complete urticaria clearance rates of 43% to 54%, substantially exceeding the 11% rate in the placebo group.
Based on these results, Q BioPharma plans to begin a phase 2b/3 clinical trial in patients with chronic idiopathic urticaria.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
